Evotec SE Stock Other OTC
Equities
EVTCY
US30050E1055
Biotechnology & Medical Research
Sales 2024 * | 882M 957M 1.31B | Sales 2025 * | 1.03B 1.12B 1.53B | Capitalization | 1.57B 1.7B 2.32B |
---|---|---|---|---|---|
Net income 2024 * | -34M -36.89M -50.4M | Net income 2025 * | 31M 33.63M 45.96M | EV / Sales 2024 * | 2.09 x |
Net Debt 2024 * | 278M 302M 412M | Net Debt 2025 * | 235M 255M 348M | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
-39.5
x | P/E ratio 2025 * |
35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-18 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 23-02-06 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 12-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19-06-18 |
Roland Sackers
BRD | Director/Board Member | 56 | 19-06-18 |
Chairman | 63 | 14-06-16 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 62.86B | |
-0.77% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+13.30% | 26.46B | |
-22.79% | 18.9B | |
+4.70% | 12.67B | |
+24.10% | 12.27B | |
+27.41% | 12.07B |